Annual report pursuant to Section 13 and 15(d)

Patent and Technology License Agreements (Details)

v3.20.4
Patent and Technology License Agreements (Details) - USD ($)
1 Months Ended 12 Months Ended
Apr. 30, 2020
Oct. 06, 2020
Sep. 30, 2020
Sep. 30, 2019
Patent and Technology License Agreements (Textual)        
Maintenance fee     $ 90,000 $ 90,000
Minimum aggregate annual royalties     100,000  
Increasing annual royalties     25,000  
Maximum aggregate annual royalties     150,000  
Payable amount to NAT     $ 1,100,000  
Nonrefundable upfront payment       $ 125,000
Description of license agreement     We paid an annual maintenance fee of $30,000 in January 2020. The annual maintenance fee increases by $15,000 per year up to a maximum of $90,000. Annual maintenance fees cease on the first sale of product. We also must pay up to an aggregate of $2.1 million in milestone payments, contingent on the achievement of various regulatory and commercial milestones. Under the terms of the license agreement, we also must pay a royalty of mid- to upper-single digit percentages of net sales, depending on the amount of annual sales, and subject to downward adjustment to lower- to mid-single digit percentages in the event there is no valid patent for the product in the United States at the time of sale. After the first sale of product, we will owe an annual minimum royalty payment of $100,000 that will increase annually by $25,000 for the duration of the term.  
Aggregate of milestone payments     $ 2,100,000  
Annual minimum royalty payment     $ 100,000  
Agreement expiration date     Jan. 02, 2034  
Options paid $ 100,000      
Subsequent Event [Member]        
Patent and Technology License Agreements (Textual)        
Execution of agreement advance   $ 5,000,000    
Exclusive agreement, description   Exclusive agreement with Novellus and have created a subsidiary, NoveCite, that will be focused on developing cellular therapies. Upon execution of the agreement, we advanced $5,000,000 to NoveCite and issued Novellus shares of NoveCite’s common stock representing 25% of the outstanding equity. We own the other 75% of NoveCite’s outstanding equity. Pursuant to the terms of the stock subscription agreement between Novellus and NoveCite, if NoveCite issues additional equity, subject to certain exceptions, NoveCite must maintain Novellus’s ownership at 25% by issuing additional shares to Novellus.    
Developmental milestone, description   NoveCite is obligated to pay Novellus up to $51,000,000 upon the achievement of various regulatory and developmental milestones. NoveCite also must pay a royalty equal to low double-digit percentages of net sales, commencing upon the sale of a licensed product. This royalty is subject to downward adjustment to an upper-single digit percentage of net sales in any country in the event of the expiration of the last valid patent claim or if no valid patent claim exists in that country. The royalty will end on the earlier of (i) date on which a biosimilar product is first marketed, sold, or distributed in the applicable country or (ii) the 10-year anniversary of the date of expiration of the last-to-expire valid patent claim in that country. In the case of a country where no licensed patent ever exists, the royalty will end on the later of (i) the date of expiry of such licensed product’s regulatory exclusivity and (ii) the 10-year anniversary of the date of the first commercial sale of the licensed product in the applicable country. In addition, NoveCite will pay to Novellus an amount equal to a mid-twenties percentage of any sublicensee fees it receives. Under the terms of the license agreement, in the event that Novellus receives any revenue involving the original cell line included in the licensed technology, then Novellus shall remit to NoveCite 50% of such revenue.